Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
申请人:Caprathe William Bradley
公开号:US20050096327A1
公开(公告)日:2005-05-05
This invention relates to compounds of the formula 1
wherein R
1
, R
2
, and R
3
and R
4
are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.
USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS
申请人:Wynne Graham Michael
公开号:US20100317607A1
公开(公告)日:2010-12-16
Compounds of a compound of compound of general formula (I) wherein X
1
, X
2
, A, R
1
R
2
, R
3
and R
4
are as defined herein; are useful as anti-mycobacterial agents, especially agents for the treatment of tuberculosis.
Efficient synthesis of quinazoline-2,4(1H,3H)-diones from CO<sub>2</sub> catalyzed by N-heterocyclic carbene at atmospheric pressure
作者:Yunqing Xiao、Xianqiang Kong、Zhicheng Xu、Changsheng Cao、Guangsheng Pang、Yanhui Shi
DOI:10.1039/c4ra13752c
日期:——
Under atmospheric pressure, quinazoline-2,4(1H,3H)-diones were obtained from the reaction of 2-aminobenzonitriles with carbon dioxide (0.1 MPa) with a catalytic amount of N-heterocyclic carbene in DMSO. It was found that various electron-donating and electron-withdrawing groups such as –OMe, –F, –Cl, –Br, –CH3, –CF3 and –CN were well tolerated to give the products in almost quantitative yields.
A class of 2-aryl-4-aminoquinazoline derivatives (7a-7j, 8a-8h, 9a-9h and 10a-10k) were designed, synthesized and evaluated as EGFR inhibitors. The anti-proliferativeactivity of compounds in vitro showed that compound 9e was considered to be a promising derivative. Compared with the lead compound Angew2017-7634-1, 9e exhibited excellent inhibitory activity against A549, NCI-H460 and H1975 cell lines